Can I Take Glutathione with Reclast (Zoledronic Acid)?

What Reclast does, and what the label watches

Zoledronic acid is an intravenous bisphosphonate that inhibits osteoclast-mediated bone resorption. It binds to bone mineral with high affinity, and the label credits that binding for its long duration of action [1]. Reclast is 5 mg infused over no less than 15 minutes: once a year for osteoporosis treatment, every 2 years for prevention of postmenopausal osteoporosis, and once for Paget's disease [1].

The renal rules in the label are precise. Reclast is contraindicated at a creatinine clearance below 35 mL/min or with evidence of acute renal impairment [1]. The label says creatinine clearance is calculated with the Cockcroft-Gault formula on actual body weight before each dose, and that patients must be adequately hydrated before the infusion [1]. Acute renal failure has followed a single dose, with rare hospitalization, dialysis or fatal outcomes in patients who had moderate to severe renal impairment or risk factors including advanced age, dehydration, diuretics and nephrotoxic drugs such as NSAIDs [1]. In the 3-year osteoporosis trial of 7,736 women, a transient creatinine rise within 10 days occurred in 1.8% on Reclast versus 0.8% on placebo [1].

Where glutathione sits in that label

The drug interactions section names aminoglycosides, loop diuretics, potentially nephrotoxic drugs such as NSAIDs, and drugs primarily excreted by the kidney [1]. It also states that no in vivo drug interaction studies were performed for Reclast at all [1]. Glutathione is not named there. Zoledronic acid is not metabolized and is excreted unchanged in urine [1].

The documented harm with glutathione injections

FDA's approved-drug database lists no glutathione injection. The only FDA-approved product containing glutathione that I could find is BSS PLUS, an irrigating solution used during eye surgery [5].

In June 2019, FDA reported seven patients at an outpatient clinic who received 1,400 mg of injectable glutathione compounded from supplement-grade L-glutathione. Within minutes they had nausea, vomiting, lightheadedness, chills, body aches and sneezing; one had low blood pressure and difficulty breathing and was transferred to a hospital. Samples from the repackager and the pharmacy all contained excessive bacterial endotoxin, some as high as five times the appropriate limit [2].

On August 27, 2026, FDA said it was aware of at least 30 patients with adverse events after intravenous glutathione, alone or with other ingredients: fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms, some requiring hospitalization. FDA said these symptoms are consistent with exposure to excessive endotoxin, which can be fatal. Several compounding pharmacies had obtained the glutathione from a single supplier lot labeled dietary supplement grade, which FDA says is not an appropriate ingredient for injectables [3]. FDA's advice to health care professionals is to ask their compounder where the glutathione comes from [3].

FDA posted three recalls of compounded glutathione products in August and September 2026 for elevated endotoxin levels; one of them followed nine reports of fever, chills, chest pain, nausea or vomiting, headache and malaise [6][7][8].

FDA lists glutathione in category 1 ("bulk drug substances under evaluation") on its compounding lists [14][15]. Under that category FDA does not intend to take action against a compounder if the conditions in its guidance are met [9]. Category 1 is not an approval and not a finding that injectable glutathione is safe.

Injectable glutathione also leaves the blood quickly. In 10 healthy volunteers, a 2 g/m2 infusion raised plasma total glutathione from about 17.5 to 823 micromol/L, with a half-life of about 14 minutes [10].

Oral glutathione is a different exposure

A 6-month randomized trial in 54 non-smoking adults found that 1,000 mg a day of oral glutathione raised levels 30% to 35% in red cells, plasma and lymphocytes (260% in cheek cells), while 250 mg a day raised blood glutathione 17% and red-cell glutathione 29%; levels returned to baseline after a 1-month washout [4]. Oral glutathione was well tolerated in a 4-week trial of 60 medical students taking 500 mg a day [11]. In a 30-day follow-up of 14 healthy adults taking a micellar formulation at 600 mg a day, ALT, AST, ALP and creatinine did not change significantly [12]. None of these studies enrolled people receiving bisphosphonates.

After the infusion: what the label expects

The acute-phase reaction is common and expected. In an analysis of 7,765 women, 42.4% of those on zoledronic acid had one after the first infusion versus 11.7% on placebo, with peak onset within a day and a median duration of 3 days [13]. The Reclast label lists fever in 18%, myalgia in 9%, flu-like symptoms in 8%, headache in 7% and arthralgia in 7%, mostly in the first 3 days and usually resolving within 3 days (up to 7 to 14). Symptoms are fewer with later doses, and acetaminophen after the infusion may reduce them [1].